Trastuzumab emtansine

Brand name: Kadcyla

DILI Likelihood

Score B — Known Hepatotoxin

This drug is known or highly likely to cause idiosyncratic liver injury and has a characteristic signature.

Between 12 and 50 cases including small case series have been described in the medical literature.

Classification

Primary class Antineoplastic

Secondary class Breast Cancer: HER2

FDA approval 2013